AVTX · Insider Trading
Avalo Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by AVTX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Rita Jain | Director | A | +1,322 deriv. | — |
| 2026-10-02 | Ron M Philip | Director | A | +1,109 deriv. | — |
| 2026-10-02 | Kevin Robert Lind | Director | A | +1,352 deriv. | — |
| 2026-09-18 | Christopher Ryan Sullivan | Chief Financial Officer | MIXED | — | −$79.98K |
| 2026-09-11 | Christopher Ryan Sullivan | Chief Financial Officer | MIXED | — | −$97.57K |
| 2026-09-01 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$8.12K |
| 2026-08-19 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$7.35K |
| 2026-08-19 | Christopher Ryan Sullivan | Chief Financial Officer | MIXED | −873 | −$740.52K |
| 2026-08-12 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$8.12K |
| 2026-08-12 | Jennifer Riley | Chief Strategy Officer | Sell | −2,655 | −$52.01K |
| 2026-07-29 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$7.35K |
| 2026-07-02 | Kevin Robert Lind | Director | A | +1,105 deriv. | — |
| 2026-07-02 | Rita Jain | Director | A | +1,080 deriv. | — |
| 2026-07-02 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$42.41K |
| 2026-07-02 | Ron M Philip | Director | A | +69 deriv. | — |
| 2026-06-25 | Ron M Philip | Director | A | +40,200 deriv. | — |
| 2026-06-25 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$14.44K |
| 2026-06-12 | Paul Varki | Chief Legal Officer | F | −1,081 | −$14.16K |
| 2026-06-12 | Mittie Doyle | Chief Medical Officer | F | −1,084 | −$14.20K |
| 2026-06-12 | Christopher Ryan Sullivan | Chief Financial Officer | F | −138 | −$1.81K |
| 2026-06-12 | Jennifer Riley | Chief Strategy Officer | F | −588 | −$7.70K |
| 2026-06-04 | Rita Jain | Director | A | +20,100 deriv. | — |
| 2026-06-04 | Gilla Kaplan | Director | A | +20,100 deriv. | — |
| 2026-06-04 | Kevin Robert Lind | Director | A | +20,100 deriv. | — |
| 2026-06-04 | Michael Thomas Heffernan | Director | A | +29,500 deriv. | — |
| 2026-06-04 | Samantha Truex | Director | A | +20,100 deriv. | — |
| 2026-06-04 | Aaron Kantoff | Director | A | +20,100 deriv. | — |
| 2026-06-01 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$5.40K |
| 2026-05-26 | Paul Varki | Chief Legal Officer | A | +24,300 | — |
| 2026-05-26 | Garry Arthur Neil | Chief Executive Officer | A | +100,200 | — |
| 2026-05-26 | Mittie Doyle | Chief Medical Officer | A | +43,500 | — |
| 2026-05-26 | Jennifer Riley | Chief Strategy Officer | A | +34,200 | — |
| 2026-05-26 | Christopher Ryan Sullivan | Chief Financial Officer | A | +39,900 | — |
| 2026-05-19 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$18.33K |
| 2026-05-11 | Christopher Ryan Sullivan | Chief Financial Officer | MIXED | — | −$264.99K |
| 2026-05-07 | Mitchell Chan | Director | Sell | −3,167 | −$72.46K |
| 2026-05-07 | Paul Varki | Chief Legal Officer | MIXED | — | −$573.29K |
| 2026-05-07 | Christopher Ryan Sullivan | Chief Financial Officer | MIXED | — | −$570.84K |
| 2026-05-07 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$996.41K |
| 2026-05-01 | Christopher Ryan Sullivan | Chief Financial Officer | Sell | −16,915 | −$222.59K |
| 2026-04-08 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$21.29K |
| 2026-04-03 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$5.40K |
| 2026-04-03 | Christopher Ryan Sullivan | Chief Financial Officer | Sell | −15,959 | −$270.59K |
| 2026-04-01 | Rita Jain | Director | A | +1,339 deriv. | — |
| 2026-04-01 | Kevin Robert Lind | Director | A | +1,370 deriv. | — |
| 2026-03-18 | Mittie Doyle | Chief Medical Officer | MIXED | — | −$116.76K |
| 2026-03-02 | Garry Arthur Neil | Chief Executive Officer | A | +286,000 deriv. | — |
| 2026-03-02 | Christopher Ryan Sullivan | Chief Financial Officer | A | +105,000 deriv. | — |
| 2026-03-02 | Taylor Boyd | Chief Business Officer | A | +95,000 deriv. | — |
| 2026-03-02 | Paul Varki | Chief Legal Officer | A | +80,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Garry Arthur Neil | Chief Executive Officer | 190,314 | $1.29M |
| Mittie Doyle | Chief Medical Officer | 52,455 | $355.12K |
| Christopher Ryan Sullivan | Chief Financial Officer | 52,294 | $354.03K |
| Jennifer Riley | Chief Strategy Officer | 37,041 | $250.77K |
| Paul Varki | Chief Legal Officer | 32,576 | $220.54K |
| Jonathan Goldman | Director | 8,200 | $55.51K |
| June Sherie Almenoff | Director | 4,167 | $28.21K |
| Gilla Kaplan | Director | 3,167 | $21.44K |
| Aaron Kantoff | Director | 3,167 | $21.44K |
| Samantha Truex | Director | 3,167 | $21.44K |
| Mitchell Chan | Director | 3,166 | $21.43K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AVTX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.